Pfizer: A High-Yield Pharma At A Turning Point [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
I believe retail investors' fears about the end of exclusivity for Pfizer's blockbusters, such as Xeljanz and Ibrance, in 2026-2028, are overblown. This is because Pfizer has a strong pipeline of FDA-approved cancer drugs and vaccines, as well as potentially best-in-class GLP-1/amylin-based therapies, MET-097i/MET-233i. Moreover, Pfizer shares are traded at a non-GAAP P/E ratio [FWD] of 8.49x, which is significantly lower than those of its key competitors, including AbbVie, Merck, and Eli Lilly. Coupled with its dividend yield exceeding 6% and with the Fed expected to continue cutting interest rates in 2026, I believe the risk/reward ratio of Pfizer is more than attractive right now. Prostock-Studio/iStock via Getty Images Since my November article , "Pfizer: Is This Pharma Giant Finally A Bargain", Pfizer stock ( PFE ) has risen 5.6%, outperforming the 'barometer' for the biotech investors, the iShares Biotechnology ETF ( IBB ) [5.2% return], as This article was written
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies [Yahoo! Finance]Yahoo! Finance
- Pfizer (NYSE:PFE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Pfizer (NYSE:PFE) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership [Yahoo! Finance]Yahoo! Finance
- Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 1/16/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- PFE's page on the SEC website